Ekso Bionics prices 769,490 shares at $4.81 in registered direct offering

Ekso Bionics (EKSO) entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 769,490 shares of the Company’s common stock at a purchase price of $4.81 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about October 30, 2025, subject to the satisfaction of customary closing conditions. Lake Street Capital Markets is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be $3.7M, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including, but not limited to, research and development activities, selling, general and administrative costs, strategic initiatives and to meet working capital needs.